Edwards Lifesciences Q4 Preview: PASCAL and EVOQUE Systems to Boost TAVR Sales
Edwards Lifesciences is set to report fourth-quarter results Feb 10, following expected 9.1% medtech sector revenue growth despite a 1.5% earnings decline. Its Transcatheter Aortic Valve Replacement arm, driven by PASCAL and EVOQUE system rollouts, is predicted to lead sales gains across key global markets.
1. Sector Q4 Performance Forecast
Medtech sector’s fourth-quarter earnings are forecast to decline 1.5% year over year on 9.1% revenue growth, driven by digital health device adoption, robotics, and AI. M&A activity totaled $43.4 billion across 27 deals in the quarter, supporting innovation but pressuring margins in pricing-sensitive markets like China.
2. Edwards Lifesciences Q4 Outlook
Edwards Lifesciences will report Q4 on Feb. 10, with its Transcatheter Aortic Valve Replacement unit expected to lead growth. Increased uptake of PASCAL and EVOQUE valve systems, alongside guideline updates and expanded educational programs, is projected to bolster global TAVR sales and drive segment profitability.